Almirall Partners with CrystalO to Discover Novel Dermatology Drugs
Barcelona, Spain, August 9, 2026 Almirall announced a collaboration and licensing agreement with CrystalO, a China-based biotechnology company, to...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Barcelona, Spain, August 9, 2026 Almirall announced a collaboration and licensing agreement with CrystalO, a China-based biotechnology company, to...
Boston, MA, August 9, 2026 Asimov announced the successful completion of a cell line development campaign in collaboration with...
CAMBRIDGE, UK, July 23, 2026 AstraZeneca has secured European Commission approval for Etcamah (camizestrant) in combination with a CDK4/6...
WALTHAM, Mass. & BOTHELL, Wash., July 22, 2026 Repligen Corporation has announced a definitive agreement to acquire BioLife Solutions...
CRANBURY, New Jersey / SUZHOU, China | July 9, 2026 Porton Advanced, a leading Advanced Therapy Medicinal Products (ATMP)...
HEBEI, China | July 9, 2026 WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has...
INCHEON, South Korea and SAN DIEGO, June 21, 2026 LOTTE Biologics has announced the successful completion of major construction...
GALWAY, Ireland, June 3, 2026 Medtronic has announced a series of major regulatory and clinical milestones aimed at significantly...
WALNUT CREEK, California, USA & SUZHOU, China | June 3, 2026 Dark Horse Consulting Group (DHCG) and Altruist Biologics...
SUZHOU, China, May 26, 2026 WuXi Vaccines, a wholly owned subsidiary of WuXi Biologics specializing in vaccine Contract Development...
